The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
p53 Status and the Efficacy of Cancer Therapy in Vivo
Abstract
The therapeutic responsiveness of genetically defined tumors expressing or devoid of the p53 tumor suppressor gene was compared in immunocompromised mice. Tumors expressing the p53 gene contained a high proportion of apoptotic cells and typically regressed after treatment with gamma radiation or adriamycin. In contrast, p53-deficient tumors treated with the same regimens continued to enlarge and contained few apoptotic cells. Acquired mutations in p53 were associated with both treatment resistance and relapse in p53-expressing tumors. These results establish that defects in apoptosis, here caused by the inactivation of p53, can produce treatment-resistant tumors and suggest that p53 status may be an important determinant of tumor response to therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation.
Gavrieli, Y., Sherman, Y., & Ben-Sasson, S. A. (1992) · The Journal of cell biology · doi:10.1083/jcb.119.3.493 · Cited by 9,444
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
Induction of apoptosis in fibroblasts by c-myc protein
Evan, G. I., Wyllie, A. H., Gilbert, C. S., Littlewood, T. D., Land, H., Brooks, M., Waters, C. M., Penn, L. Z., & Hancock, D. C. (1992) · Cell · doi:10.1016/0092-8674(92)90123-t · Cited by 2,935
p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
Lowe, S. W., Ruley, H. E., Jacks, T., & Housman, D. E. (1993) · Cell · doi:10.1016/0092-8674(93)90719-7 · Cited by 2,925
Self-citationApoptosis. Its significance in cancer and cancer Therapy
Kerr, J. F. R., Winterford, C. M., & Harmon, B. V. (1994) · Cancer · doi:10.1002/1097-0142(19940415)73:8<2013::aid-cncr2820730802>3.0.co;2-j · Cited by 2,132
Effects of an Rb mutation in the mouse
Jacks, T., Fazeli, A., Schmitt, E. M., Bronson, R. T., Goodell, M. A., & Weinberg, R. A. (1992) · Nature · doi:10.1038/359295a0 · Cited by 1,755
Self-citationMice deficient for Rb are nonviable and show defects in neurogenesis and haematopoiesis
Lee, E. Y.-H. P., Chang, C.-Y., Hu, N., Wang, Y.-C. J., Lai, C.-C., Herrup, K., Lee, W.-H., & Bradley, A. (1992) · Nature · doi:10.1038/359288a0 · Cited by 1,265
Requirement for a functional Rb-1 gene in murine development
Clarke, A. R., Maandag, E. R., van Roon, M., van der Lugt, N. M. T., van der Valk, M., Hooper, M. L., Berns, A., & te Rielef, H. (1992) · Nature · doi:10.1038/359328a0 · Cited by 1,008
p53-Dependent apoptosis suppresses tumor growth and progression in vivo
Symonds, H., Krall, L., Remington, L., Saenz-Robles, M., Lowe, S., Jacks, T., & Van Dyke, T. (1994) · Cell · doi:10.1016/0092-8674(94)90534-7 · Cited by 880
Self-citationp53 and E2F-1 cooperate to mediate apoptosis.
Wu, X., & Levine, A. J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.3602 · Cited by 839
p53-dependent apoptosis produced by Rb-deficiency in the developing mouse lens
Morgenbesser, S. D., Williams, B. O., Jacks, T., & DePinho, R. A. (1994) · Nature · doi:10.1038/371072a0 · Cited by 610
Self-citationTanaka, N., Ishihara, M., Kitagawa, M., Harada, H., Kimura, T., Matsuyama, T., Lamphier, M. S., Aizawa, S., Mak, T. W., & Taniguchi, T. (1994) · Cell · doi:10.1016/0092-8674(94)90132-5 · Cited by 491
Fujiwara, T., Grimm, E. A., Mukhopadhyay, T., Zhang, W. W., Owen‐Schaub, L. B., & Roth, J. A. (1994) · PubMed · Cited by 464
Drug-target interactions: only the first step in the commitment to a programmed cell death?
Dive, C., & Hickman, J. (1991) · British Journal of Cancer · doi:10.1038/bjc.1991.269 · Cited by 398
el Rouby, S., Thomas, A., Costin, D., Rosenberg, C., Potmesil, M., Silber, R., & Newcomb, E. (1993) · Blood · doi:10.1182/blood.v82.11.3452.3452 · Cited by 374
Anaplastic Wilms' tumour, a subtype displaying poor prognosis, harbours p53 gene mutations
Bardeesy, N., Falkoff, D., Petruzzi, M.-J., Nowak, N., Zabel, B., Adam, M., Aguiar, M. C., Grundy, P., Shows, T., & Pelletier, J. (1994) · Nature Genetics · doi:10.1038/ng0594-91 · Cited by 339
Abrogation of oncogene-associated apoptosis allows transformation of p53-deficient cells.
Lowe, S. W., Jacks, T., Housman, D. E., & Ruley, H. E. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.6.2026 · Cited by 287
Self-citationLotem, J., & Sachs, L. (1993) · PubMed · Cited by 282
Analysis of the gene coding for the murine cellular tumour antigen p53.
Bienz, B., Zakut-Houri, R., Givol, D., & Oren, M. (1984) · The EMBO Journal · doi:10.1002/j.1460-2075.1984.tb02110.x · Cited by 167
Somatic p53 mutations in human breast carcinomas in an Icelandic population: a prognostic factor.
Thorlacius, S., Børresen‐Dale, A., & Eyfjörd, J. E. (1993) · PubMed · Cited by 119
Hsiao, M., Yu, A. L.-T., Yeargin, J., Ku, D., & Haas, M. (1994) · Blood · doi:10.1182/blood.v83.10.2922.2922 · Cited by 82
Cited by
Apoptosis in the Pathogenesis and Treatment of Disease
Thompson, C. B. (1995) · Science · doi:10.1126/science.7878464 · Cited by 6,524
Ko, L. J., & Prives, C. (1996) · Genes & Development · doi:10.1101/gad.10.9.1054 · Cited by 2,344
Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours
Graeber, T. G., Osmanian, C., Jacks, T., Housman, D. E., Koch, C. J., Lowe, S. W., & Giaccia, A. J. (1996) · Nature · doi:10.1038/379088a0 · Cited by 2,300
Self-citationDeath and anti-death: tumour resistance to apoptosis
Igney, F. H., & Krammer, P. H. (2002) · Nature Reviews Cancer · doi:10.1038/nrc776 · Cited by 2,075
ROS signalling in the biology of cancer
Moloney, J. N., & Cotter, T. G. (2018) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2017.05.023 · Cited by 1,970
Metadata
- Authors
- Lowe, S. W., Bodis, S., McClatchey, A., Remington, L., Ruley, H. E., Fisher, D. E., Housman, D. E., & Jacks, T.
- Venue
- Science
- Published
- 1994-11-04
- Volume
- 266
- Issue
- 5186
- Pages
- 807-810
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2081894694
- Cited by
- 1,469
- References
- 21
- FWCI
- 38.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.